About Syntaxin
Syntaxin is based in corporate laboratories in Abingdon UK with 46 employees, with proven capability in research, process development, preclinical evaluation, manufacture and clinical study of its proprietary cell secretion inhibitors. Preclinical, drug supply and clinical trial capabilities are extensively outsourced by the experienced management team.
Syntaxin has deep expertise in the design and development of a new class of biopharmaceuticals termed Targeted Secretion Inhibitors (TSI) that selectively inhibit the secretory process in cells for the treatment of hyper and inappropriate secretory disorders across a range of therapeutic areas.
Syntaxin’s TSI have the potential to be potent drugs that can be administered locally or systemically with duration of action from weeks to months from a single dose.
TSI have potential in the treatment of diseases involving cell secretion, for example:
- CNS/PNS disorders (e.g. Pain, neuromuscular disorders)
- Endocrine disorders (e.g. Acromegaly, hyperparathyroidism)
- Tissue healing and repair, (e.g. where controlled muscle relaxation would benefit)
- Oncology, (e.g. hyperproliferative disorders)
Syntaxin has a dominant IP position in regard to its TSI technology with an extensive patent portfolio, currently consisting of 46 granted patents with a further 70 patent applications pending, in all the major world markets.
Opportunities exist for partnerships to select novel targeting domains for TSI for particular applications where the intracellular domains have been designed to selectively attenuate drivers of target diseases.
Series B financing of $32m was finalised in October 2007. The fundraising round was co-led by new investors SR One, the venture capital arm of GSK, one of the world's leading research-based pharmaceutical and healthcare companies, and LSP (Life Science Partners) with additional funds from Syntaxin's existing shareholders, Abingworth. New investors Johnson & Johnson Development Corporation (JJDC) and Quest for Growth also participated in the financing.
